Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence
Jan‐Niklas Eckardt(Klinik und Poliklinik für Psychotherapie und Psychosomatik), Jan Moritz Middeke(Fresenius (Germany)), Martin Bornhäuser(Technische Universität Dresden), Carsten Müller‐Tidow(Heidelberg University), Claudia D. Baldus(University Hospital Schleswig-Holstein), Markus Wolfien(German Research Centre for Artificial Intelligence), Christoph Schliemann(University Hospital Münster), Martin Sedlmayr(Zimmer Biomet (Germany)), Andreas Burchert(Philipps University of Marburg), Sebastian Stasik(University Hospital Carl Gustav Carus), Maher Hanoun(Essen University Hospital), Uwe Platzbecker(National Center for Tumor Diseases), Hubert Serve(Goethe University Frankfurt), Waldemar Hahn(Zimmer Biomet (Germany)), Martin Kaufmann(Robert Bosch Hospital), Kerstin Schäfer‐Eckart(Nuremberg Hospital), Johannes Schetelig(University Hospital Carl Gustav Carus), Christian Thiede(University Hospital Carl Gustav Carus), Christoph Röllig(University Hospital Carl Gustav Carus)
Cited by 58
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
The future landscape of large language models in medicine
|Communications Medicine|2023|937